Research and Markets: Neuroendocrine Tumors - Pipeline Review, H2 2012

Fri Nov 23, 2012 4:48am EST

* Reuters is not responsible for the content in this press release.

Research and Markets: Neuroendocrine Tumors - Pipeline Review, H2 2012

Research and Markets has announced the addition of Global Markets Direct's new report "Neuroendocrine Tumors - Pipeline Review, H2 2012" to their offering.

Global Markets Direct's, 'Neuroendocrine Tumors - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Neuroendocrine Tumors, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuroendocrine Tumors.

Scope

- A snapshot of the global therapeutic scenario for Neuroendocrine Tumors.

- A review of the Neuroendocrine Tumors products under development by companies and universities

research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Neuroendocrine Tumors pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- News and deals relating to the products.

Reasons to Buy

- Identify and understand important and diverse types of therapeutics under development for Neuroendocrine Tumors.

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Neuroendocrine Tumors pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit http://www.researchandmarkets.com/research/z42jb8/neuroendocrine

Source: Global Markets Direct

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.